GlaxoSmithKline Pharmaceuticals reported a 5.68% increase in standalone net profit to ₹274.94 crore for the fourth quarter of FY26, compared to the same period last year. Revenue from operations rose by 2.38% to ₹989.15 crore. Profit before tax also saw a 4% increase, reaching ₹369.12 crore. Total expenses rose slightly by 0.78% to ₹655.75 crore. The company's EBITDA increased by 5%, improving the margin by 90 basis points to 35.1%. Key brands in the General Medicines portfolio, including Augmentin and Calpol, maintained strong market positions, while the Vaccines segment benefited from heightened demand. The Oncology division, particularly therapies like Jemperli and Zejula, showed significant growth, with Jemperli receiving regulatory approval for treating advanced endometrial cancer. GSK India’s Managing Director, Bhushan Akshikar, emphasized the company's commitment to innovation and growth. The board has proposed a final dividend of ₹57 per equity share for the fiscal year ending March 31, 2026, with a record date set for May 29, 2026. Shares of GSK Pharma closed down 1.68% at ₹2,406.85 on the Bombay Stock Exchange.